

American Society of Clinical Oncology  
Genitourinary Cancers Symposium  
**2023 ASCO GU  
Cancers Symposium**

February 16-18, 2023



The compilation of presentations is for educational purposes only. Copies of presentations obtained through quick response (QR) codes are live the day of the presentation, and **per the meeting's guidelines, the QR code links to either the Pfizer Conference Publications Portal or the conference website for obtaining the presentation. Copies of presentations obtained through QR codes are for personal use only and may not be reproduced without permission from the conference and the author of those presentations.** All copyrights protected by law. Solely for non-commercial use.

## Pfizer/Astellas-Sponsored Oral Presentation

### Oral Abstract Session A: Prostate Cancer

Thursday, February 16

7:45 AM – 9:30 AM (PST)

**Talazoparib**

**Presentation LBA17**

**8:00 AM – 8:10 AM**

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Agarwal N

*Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.*

[View Presentation](#)

## Pfizer/Alliance-Sponsored Poster Presentations

### Poster Session A: Prostate Cancer

Thursday, February 16

11:30 AM – 1:00 PM; 5:45 PM – 6:45 PM (PST)

**Presentation 25**

Social determinants of health (SDOH) and survival among patients with metastatic prostate cancer (mPC): A systematic literature review (SLR)

Freedland S

[View Presentation](#)

**Talazoparib**

**Presentation 26**

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-sensitive prostate cancer

DerSarkissian M

[View Presentation](#)

---

**Talazoparib****Presentation 29**

Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer

DerSarkissian M

[View Presentation](#)

---

**Relugolix****Presentation 74**

Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database

McKay R

*Presentation is supported by Myovant and Pfizer Alliance.*

[View Presentation](#)

---

**Relugolix****Presentation 82**

Association of intermittent vs continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with metastatic prostate cancer

Morgans A

*Presentation is supported by Myovant and Pfizer Alliance.*

[View Presentation](#)

---

**Relugolix****Presentation 83**

Association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer

Morgans A

*Presentation is supported by Myovant and Pfizer Alliance.*

[View Presentation](#)

---

**Relugolix****Presentation 94**

Identifying prostate cancer patient subgroups based on their preferences for key attributes of androgen deprivation therapies

Collins S

*Presentation is supported by Myovant and Pfizer Alliance.*

[View Presentation](#)

---

**Talazoparib****Presentation 95**

Real world (rw) racial differences in treatment (tx) patterns and clinical outcomes among patients (pts) with mCRPC

Barata P

[View Presentation](#)

---

**Talazoparib****Presentation 98**

Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US)

Barata P

[View Presentation](#)

---

**Talazoparib****Presentation 99**

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US)

Barata P

[View Presentation](#)

---

**Enzalutamide****Presentation 109**

Real-world (RW) prevalence of adverse events (AEs) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Swami U

*Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.*[View Presentation](#)

---

**Trials in Progress Poster Session A:  
Prostate Cancer**

Thursday, February 16

11:30 AM – 1:00 PM; 5:45 PM – 6:45 PM (PST)

---

**Talazoparib****Presentation TPS279**

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC)

Agarwal N

*Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.*[View Presentation](#)

---

**PF-06821497****Presentation TPS282**

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Calvo M

[View Presentation](#)

---

**Relugolix****Presentation TPS398**

A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX

Spratt D

*Presentation is supported by Myovant and Pfizer Alliance.*[View Presentation](#)

---

**Poster Session B:  
Prostate Cancer and Urothelial Carcinoma**

Friday, February 17

12:30 PM – 2:00 PM; 5:15 PM – 6:15 PM (PST)

---

**Talazoparib****Presentation 97**

The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US)

Barata P

[View Presentation](#)

---

**Enzalutamide****Presentation 100**

Patient (Pt) perspective on fatigue and its management for advanced prostate cancer (PC) treated with androgen receptor inhibitors (ARIs)

Freedland S

*Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.*

[View Presentation](#)

---

**Presentation 124**

The prognostic value of ECOG performance status on overall survival among patients with metastatic prostate cancer: A systematic review of the literature and meta-analysis

Assayag J

[View Presentation](#)

---

**Avelumab****Presentation 464**

Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: A retrospective analysis of real-world data in Germany

Niegisch G

*Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

**Avelumab****Presentation 465**

Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II)

Grivas P

*Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

**Avelumab****Presentation 468**

Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US

Kirker M

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

**Avelumab****Presentation 469**

READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)

Antonuzzo L

*Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

**Avelumab****Presentation 471**

Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC)

Barthélémy P

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

**Sasanlimab****Presentation 473**

Time to event following bacillus Calmette-Guerin therapy initiation in Medicare beneficiaries with intermediate- to high-risk non-muscle invasive bladder cancer, 2010-2019

Petrilla A

[View Presentation](#)

---

**Sasanlimab****Presentation 479**

Economic impact of bladder cancer (BC) in the United States (US)

Clark O

[View Presentation](#)

---

**Avelumab****Presentation 508**

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy

Sridhar S

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

**Avelumab****Presentation 572**

Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US

Kearney M

*Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

## **Trials in Progress Poster Session B: Urothelial Carcinoma**

Friday, February 17

12:30 PM – 2:00 PM; 5:15 PM – 6:15 PM (PST)

---

**Avelumab****Presentation TPS577**

SPADE: Design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region

SU P

*Presentation is sponsored by Merck KGaA, Darmstadt, Germany, as part of a strategic global alliance with Pfizer Inc. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

## Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

---

Saturday, February 18

7:00 AM – 8:00 AM; 12:30 PM – 2:00 PM (PST)

---

### Avelumab

**Presentation 631**

A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results

Nathan P

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

### Avelumab

**Presentation 670**

C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101

Tomita Y

*Presentation is sponsored by Pfizer Inc. as part of a strategic global alliance with Merck KGaA, Darmstadt, Germany. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany.*

[View Presentation](#)

---

### Axitinib

**Presentation 673**

Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Lemelin A

[View Presentation](#)

---

## Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

---

Saturday, February 18

7:00 AM – 8:00 AM; 12:30 PM – 2:00 PM (PST)

---

### PF-07265807

**Presentation TPS743**

Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma—A phase 1, open-label, pharmacokinetic, safety and tolerability study

Hirohashi T

[View Presentation](#)